Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program could run into problems with voluntary participation and concerns about expense.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.